1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Abstract
About 10% of EGFR mutations (EGFRmut) are ‘uncommon mutations’ (ucEGFRmut), correlating with lower response to 1st & 2nd generation EGFR inhibitors (EGFRi) compared to common mutations. Osimertinib is a 3rd generation EGFRi, active against common EGFRmut. Efficacy data of osimertinib in ucEGFRmut are scarce. We aimed to collect real-world data of the usage of osimertinib as the 1st EGFRi for ucEGFRmut. This is a multi-center, international,...
Paper Details
Title
1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Published Date
Sep 1, 2021
Journal
Volume
32
Pages
S961 - S962
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History